Kornimate/medical-research-clean huggingface dataset:
swiss chiropractic cohort (swiss chico) study: a nationwide practice-based research network project

Conditions: Musculoskeletal Pain

Summary: the swiss chiropractic cohort (swiss chico) practice-based research network (pbrn) is nationwide research project with the aim to develop a musculoskeletal focused pbrn within the swiss chiropractic setting and describe the characteristics of clinicians recruited. development of the pbrn has been guided through participatory engagement of multiple stakeholders including patients, clinicians, scientists, and policymakers.

management of musculoskeletal (msk) conditions is moving away from traditional medical treatments such as pain medication and towards more physical and preventative approaches. as a result, there is a need to describe manual care approaches to make informed decisions on how best to use this capacity in the current health care system. while this literature is emerging, very little is collected from clinical settings where the large majority of msk care occurs. the lack of clinically collected data creates gaps in patient-centred research and difficulties with knowledge implementation in treatment settings. to help bridge this divide, countries such as the united kingdom, canada, sweden, and australia have established msk-focused practice-based research networks (pbrns). pbrns are sustained collaborations between practitioners and academicians. this collaboration allows patient recruitment from diverse clinical settings and allows practitioners to be more actively involved in the research process. as a result data collected, and subsequent recommendations may have greater clinical utility than that which comes from more traditional research-only settings. this study aims to develop a msk focused pbrn within the swiss chiropractic setting and describe the characteristics of clinicians recruited. it represents a collaborative effort of international researchers, swiss chiropractic clinicians, and the chiropractic patient and clinical associations in switzerland (pro chiropractic switzerland and chirosuisse). clinicians will endorse participation in the pbrn by completing an electronic study form. once established, nested sub-studies will be conducted within this new clinical research environment. through stakeholder engagement and institutional support, the swiss chico pbrn can serve as an important resource to advance chiropractic and msk health services research.

Eligibility criteria:
inclusion criteria: * active clinician members of the swiss chiropractic association (chirosuisse)

Keywords: chiropractic health care quality musculoskeletal health manual medicine
effects of tribulus terrestris in postmenopausal women with hypoactive sexual desire disorder

Conditions: Menopause; Sexual Abstinence

Summary: hypoactive sexual desire disorder ( hsdd ) is very common in postmenopausal women due to a reduction in circulating androgen levels. the aim of this study is to evaluate the effects of tribulus terrestris in premenopausal women with hsdd.

hypoactive sexual desire disorder ( hsdd ) is the most prevalent female sexual dysfunction in society mainly in postmenopausal women, and is strongly linked to the quality of life of women . the androgen hormones decline over age in the premenopausal period, more sharply after menopause. tribulus terrestris is a plant native to india , recommended in the treatment of infertility , low libido and impotence . its main active ingredient is the protodioscin , which has been attributed to an increase in testosterone levels and improved sexual function . the aim of this study is to evaluate the effects of tribulus terrestris in premenopausal women with hsdd .

Eligibility criteria:
inclusion criteria: * at least one year after last menstrual period * with no use of hormonal replacement therapy within the last 3 months * without any medication, drugs or alcohol. * healthy patients without systemic or psychiatric disease exclusion criteria: * patient smoker (10 cigarettes per day). * patients with blood pressure \> 160/90 mm hg. * patient with breast or endometrial carcinoma. * patients with a history of myocardial infarction. * patient with diabetes. * patient with vaginal bleeding from any source. * patients with hepatic injury. * patients with active thrombophlebitis or thromboembolic disorders recent * patients with interpersonal relationship problems with your relationship or partner * patients with sexual problems from your partner

Keywords: postmenopausal hypoactive sexual disorder androgen
efficacy of telbivudine treatment at long term on the absence of liver inflammation in patients with compensated chronic hepatitis b

Conditions: Compensated Chronic Hepatitis B

Summary: the purpose of this trial is to provide data of absence of inflammation in patient liver histology after long-term telbivudine treatment and thus help investigators to make a comprehensive judgment on treatment discontinuation in selected patients


Eligibility criteria:
inclusion criteria: * patient completed study cldt600acn04 study and will be available to immediately rollover into this study without discontinuation of study drug. * patient was not discontinued from the previous cldt600acn04 study. * adult patients with chb (hbeag positive or hbeag negative). * hbv dna pcr undetectable in recent 12 months. exclusion criteria: * pregnant or breastfeeding, or has plan of pregnant during study period. * patient is co-infected with hepatitis c virus (hcv), hepatitis d virus (hdv), or hiv at screening visit. * patient has received within the past 12 months any anti-hbv treatment combination (add-on therapy) or switch to other anti hbv treatment from telbivudine at investigator's discretion. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: chronic hbv
use of lactic acid gel for intravaginal use, 7 applicators x 5ml, bayer to reduce post-episiotomy discomfort

Conditions: Episiotomy; Wound Healing; Postpartum Period

Summary: this prospective controlled study evaluates the efficacy of topical lactic acid gel in enhancing episiotomy wound healing and improving postpartum sexual quality of life.

this prospective controlled clinical study aims to evaluate the efficacy of topical lactic acid gel in promoting the healing of episiotomy wounds and improving postpartum sexual quality of life. the study was conducted at the county clinical emergency hospital "sf. ap. andrei" in constanța, romania, between february 1, 2023, and december 31, 2024, with ethical approvals obtained from both the ethics committee of ovidius university of constanța (no. 01/20.01.2023) and the saint andrew hospital ethics committee (no. 7230/31.01.2023). a total of 100 postpartum women aged 18 to 40 years, who underwent spontaneous vaginal delivery with mediolateral episiotomy at a gestational age of 38-40 weeks, were enrolled in the study after providing informed consent. participants were sequentially assigned into two parallel groups: experimental group (n = 50): received topical lactic acid gel (commercially available formulation from bayer, bucharest, romania) applied once daily directly to the episiotomy site, starting seven days postpartum, for a total duration of seven consecutive days. control group (n = 50): received standard postpartum care without additional topical treatments, allowing for spontaneous healing of the episiotomy wound. the primary endpoint was the assessment of episiotomy wound healing quality at 40 days postpartum, determined via visual inspection and healing scoring. the secondary endpoint was the evaluation of postpartum sexual function, assessed using a validated 12-item sexual quality of life questionnaire specifically designed for postpartum women. the questionnaire addressed domains including sexual desire, orgasm frequency, sexual satisfaction, pain during intercourse (dyspareunia), vaginal dryness, emotional well-being during intercourse, and partner-related factors. higher total scores reflected better sexual health and satisfaction.

Eligibility criteria:
inclusion criteria: * women aged 18-40 years * spontaneous vaginal delivery with mediolateral episiotomy at 38-40 weeks gestation * no pre-existing wound healing disorders or infections * provided informed consent exclusion criteria: * known hypersensitivity to lactic acid products * third- or fourth-degree perineal tears * gestational diabetes or immunosuppressive conditions * use of additional wound care treatments

Keywords: episiotomy wound healing postpartum
hflvv for hypoxemia in robot-assisted cardiac surgery

Conditions: Hypoxemia

Summary: these robot-assisted cardiac surgeries usually require single-lung ventilation (slv) to facilitate surgical exposure. slv creates ventilation/perfusion mismatch and shunt (qs:qt) through the collapsed lung and leads to hypoxemia. pulmonary gas exchange often deteriorates after cardiopulmonary bypass (cpb) because of ischemic tissue damage. in some cases, severe hypoxemia may require the cessation of surgical procedures and the initiation of double-lung ventilation to improve oxygenation. in this study, the investigator applied the continuous positive airway pressure (cpap) or the high-frequency low-volume ventilation (hflvv) to the non-dependent lung (differential ventilation) during the weaning from cpb. the investigator hypothesized that the differential ventilation would produce the least interference with the surgeon's exposure and better oxygenation. the investigators evaluate the airway pressure, shunt fraction, pao2/fio2, cerebral oximetry, surgical field condition and the length of stay in intensive care unit of patients underwent the robot-assisted cardiac surgery.


Eligibility criteria:
inclusion criteria: * scheduled for robot-assisted cardiac surgery with cardiopulmonary bypass exclusion criteria: * age \ 70 years * pao2/fio2 ratio \< 300 mmhg before anesthesia induction * american society of anesthesiologist (asa) grade \> 3 * patients who were converted to conventional open-chest procedure
comparison of optic nerve sheath diameter on retrobulbar ultrasonography before and after drainage of cerebrospinal fluid in pediatric patient with hydrocephalus

Conditions: Hydrocephalus

Summary: studies in patients with intracranial hypertension have shown a good relationship between optic nerve sheath diameter measured by retrobulbar ultrasound and invasively measured intracranial pressure. the aim of this study was to evaluate changes in optic nerve sheath diameter before and after drainage of cerebrospinal fluid in patients with hydrocephalus.


Eligibility criteria:
inclusion criteria: 1. asa ⅰ-ⅱ 2. aged between 1 and 19 year 3. hydrocephalus 4. general anesthesia for undergoing drainage of cerebrospinal fluid exclusion criteria: 1. an anatomical or functional abnormality in optic nerve

Keywords: child optic nerve sheath diameter hydrocephalus intracranial hypertension
safety, tolerability, pharmacokinetics of intravenous rpx2003 (biapenem) in healthy adult subjects

Conditions: Healthy Volunteers; Bacterial Infections

Summary: rpx2003 (biapenem) is being studied in combination with a beta-lactamase inhibitor to treat bacterial infections, including those due to multi-drug resistant bacteria.

the worldwide spread of resistance to antibiotics among gram-negative bacteria, particularly members of the eskape group of pathogens, has resulted in a crisis in the treatment of hospital acquired infections. in particular, the recent dissemination of a serine carbapenemase (e.g., kpc) in enterobacteriaceae in us hospitals now poses a considerable threat to the carbapenems and other members of the beta-lactam class of antimicrobial agents. rempex is developing a fixed combination antibiotic of a carbapenem (rpx2003 or biapenem) plus a new beta-lactamase inhibitor (rpx7009) which has activity against serine beta-lactamases, including kpc. this phase 1 study will assess the safety, tolerability and pharmacokinetics of biapenem, administered alone, in healthy adult subjects.

Eligibility criteria:
inclusion criteria: * healthy adult males and/or females, 18 to 55 years of age * body mass index (bmi) ≥ 18.5 and ≤ 29.9 (kg/m2) and weight between 55.0 and 100.0 kg (inclusive). * medically healthy with clinically insignificant screening results * non-tobacco/nicotine-containing product users for a minimum of 6 months prior to day 1. * sexually abstinent or use acceptable methods of birth control exclusion criteria: * history or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease. * history or presence of alcoholism or drug abuse within the 2 years prior to day 1. * hypersensitivity or idiosyncratic reaction to compounds related to the study drug (e.g. beta-lactam antibiotics such as penicillins, carbapenems, etc). * history of seizures (e.g., epilepsy). * use of any over-the-counter (otc) medication, including herbal products and vitamins, within the 7 days prior to day 1. up to 2 grams per day of acetaminophen is allowed for acute events at the discretion of the pi. * blood donation or significant blood loss (i.e., \> 500 ml) within 56 days prior to day 1. * subjects who have any abnormalities on laboratory values at screening or check-in (day -1).
special drug use surveillance of irribow in female patients

Conditions: Diarrhea-predominant Irritable Bowel Syndrome

Summary: the purpose of the survey is to evaluate the safety and efficacy of irribow and irribow od tablets in post-marketing medical practice and to examine the status of treatment compliance.


Eligibility criteria:
inclusion criteria: * female patients with diarrhea-predominant irritable bowel syndrome exclusion criteria: -

Keywords: irritable bowel syndrome ym060 ramosetron survey
evaluation of the blood levels of the drug (lixisenatide), the plasma glucose levels and safety in paediatric and adult patients with type 2 diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: primary objective: - to investigate the effects of two single subcutaneous lixisenatide doses (5 and 10 µg) as compared to placebo in reducing postprandial glucose (ppg) in type 2 diabetic paediatric population (10-17 years old) and adults as controls secondary objectives: - to evaluate in both paediatric and adult populations: * the blood levels of lixisenatide (pharmacokinetic) parameters in plasma after single subcutaneous ascending doses * the maximum post-prandial glucose excursion, and on the changes in insulin, c-peptide and glucagon plasma concentrations following a standardized breakfast * safety and tolerability.

the duration of the study for each patient is planned between 4 and 7 weeks including a screening period (25 to 30 days), 3 treatment periods 1-7 days apart, each period lasting only one day (day 1) and an end-of-study visit between 1 to 7 days after the last dose administration.

Eligibility criteria:
inclusion criteria : * male or female patients with type 2 diabetes mellitus, as defined by who (fasting plasma glucose ≥ 7 mmol/l (126mg/dl) or 2 hours postprandial plasma glucose ≥ 11.1 mmol/l (200 mg/dl)), diagnosed for at least 1 year (adults) and at least 3 months for paediatric population at the time of screening visit, with or without metformin (stable dose ± 10 % for at least 4 weeks prior to randomization) * hba1c ≥ 7% and ≤ 10% at screening * age eligibility for paediatric population: ≥ 10 years and \<18 years with at least 3 patients below 15 years and no more than 3 patients aged between 16 and 18 years; age eligibility for adults: ≥ 18 and ≤ 65 years * for paediatric population:body weight \>50kg, bmi \>85th percentile for age and gender and bmi ≤ 50 kg/m² * for adults: bmi \> 25 kg/m2 and ≤ 37 kg/m2 exclusion criteria: * if female, pregnancy (defined as positive serum pregnancy test), breast-feeding * diabetes other than type 2 diabetes * positive test for insulinoma associated protein (ia2) and glutamic acid decarboxylase (gad) autoantibodies * use of other oral or injectable antidiabetic or hypoglycemic agents other than metformin (e.g., alpha glucosidase inhibitor, exenatide, dpp-iv inhibitors, insulin etc.) within 3 months prior to the time of screening * allergic reaction to any glp-1 agonist in the past (e.g. exenatide, liraglutide) or to metacresol * history of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease * personal or family history of medullary thyroid cancer (mtc) or genetic conditions that predispose to mtc (e.g., multiple endocrine neoplasia syndromes) the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
respiration and balance in adolescent volleyball players

Conditions: Adolescent Behavior; Athletic Injuries

Summary: a volleyball player with high respiratory muscle endurance can perform at a high level of efficiency during competitions without experiencing fatigue. however, no study has been found in the literature examining respiratory muscle strength, respiratory muscle endurance, cough strength and balance parameters in adolescent volleyball players which was therefore aimed to investigate the potential relationship between these parameters in this study.

professional sports performance in adolescent volleyball players who have not yet completed their developmental period may be affected in terms of respiratory muscle strength and endurance, cough strength and balance. however, no study has been found in the literature investigating the relationship between respiratory muscle strength, respiratory muscle endurance, cough strength and balance in adolescent volleyball players and these parameters. therefore, the aim of our study is to determine the relationship between respiratory muscle strength, respiratory muscle endurance, cough strength and balance in adolescent volleyball players.

Eligibility criteria:
inclusion criteria: * being between the ages of 10-19 * being actively involved in volleyball for at least 1 year * voluntarily agreeing to participate in the study * volleyball player's parent approving participation in the study exclusion criteria: * have been admitted to hospital with a musculoskeletal injury in the last 3 months * have any known neurological, orthopedic, rheumatic, and/or cardiovascular disease * have been involved in a sport other than volleyball for at least 1 year

Keywords: adolescent volleyball respiratory muscle cough balance
endometrial compaction and its influence on pregnancy rate in frozen embryo cycle regimes

Conditions: Endometrial Disorder; Infertility, Female; IVF; Pregnancy Early

Summary: for a pregnancy to occur, an euploid embryo at blastocyst developmental stage, a receptive endometrium and the synchrony of both is crucial. many studies lately investigated the influence of the endometrial thickness and pattern on the artificial reproductive technology (art) outcome, however, with conflicting results.

further on, the measurement of the endometrial thickness was mostly performed either on the day of final oocyte maturation in stimulated cycles with fresh embryo transfer or on the day of progesterone administration in fet cycles. progesterone is essential for the secretory transformation and compaction of the endometrium, prior to implantation. a recently published paper (haas et al., 2019) however, evaluated the degree of endometrial compaction under the influence of progesterone in fet cycles and described, that a lack of certain endometrial compaction has a negative impact on the ongoing pregnancy rate. as in this study embryos of unknown ploidy status were transferred, the role of embryo ploidy on the outcome may bias the study results. in the herein presented study protocol we aim to investigate the influence of endometrial compaction in fet cycles in which euploid embryos are transferred. hypothesis: lack of endometrial compaction after the start of progesterone leads to an impaired reproductive outcome.

Eligibility criteria:
inclusion criteria: * women aged 18 years to 40 years with regular menses (26-34 days) * having 1 or 2 chromosomally normal cryopreserved blastocysts available for transfer after ivf / icsi treatment * first frozen-thawed transfer cycle * progesterone level \< 1.5 ng/ml day of trigger injection in stimulation cycle from which embryos to be transferred were created. exclusion criteria: * polycystic ovarian syndrome * poor ovarian responder in accordance with bologna criteria * uterine abnormality us / saline infusion sonohysterogram * previous dilatation \& curettage (d\&c) * hydrosalpinx * asherman syndrome * history of endometriosis afs ≥ 2 * icsi due to severe male factor with testicular sperm * any known contraindications or allergy to oral estradiol or progesterone. * discontinuation of hrt medication ( medication error in research hrt cycle ) * failure to detect ovulation in the research natural cycle * ovulation after day 20 in a natural cycle * duration of estradiol exposure ≥ 17 days and endometrium \< 6mm * spontaneous ovulation in hrt artificial cycle

Keywords: infertilty progesterone endometrium pregnancy
community preparedness for outbreak response and readiness for ebola vaccination in liberia

Conditions: Ebola Virus Disease

Summary: this community-based mixed methods study intends to identify, explore, and assess the determinants of community preparedness for outbreak situations, including acceptance for ebola vaccines.

this community-based study intends to identify, explore, and assess the determinants of community preparedness for outbreak situations and acceptance for the administration of ebola vaccination. the investigators will conduct an anthropologically driven mixed methods study design that comprises both qualitative and quantitative research methods for the successful implementation of this community-based study. the investigators will conduct structured interviews with community members and local responders to broadly assess and understand the perspectives regarding appropriate strategies previously employed to effectively support community preparedness during outbreak response and also to broadly access and understand appropriate strategies previously employed to effectively support community acceptance for ebola vaccines, respectively. learning from the experiences of local voices produces globally emergent systems that are trusted, reliable and sustainable.

Eligibility criteria:
inclusion criteria: * adults * community leaders * community members * reside in 1 of 3 highly prevalent counties * participated actively in evd outbreaks related activities * documented roles recognized by the incident management system exclusion criteria: * not adults * does not reside in any of the 3 highly prevalent counties * did not actively participate in the evd outbreak response related activities * roles not documented by the incident management system

Keywords: community preparedness outbreak response ebola virus disease (evd) ebola vaccine ebola vaccine acceptance community leaders liberia